【2020 Solutions】 AI Technology Enhances Pei Yuan Health, Helping You Fulfill the Dream of Motherhood
With late marriage and childbirth becoming a trend in modern society, Taiwan has a high infertility prevalence rate of 15%, indicating that one in every seven couples faces infertility issues. Bearing children is a significant event in life, and Pei Yuan Health, through its artificial intelligence embryo testing algorithm and assisted physiological data, can enhance the success rate of artificial insemination.
For parents grappling with infertility, having a baby is a deeply cherished desire.
Statistics indicate that two-thirds of global in-vitro fertilization patients have experienced repeated failures, with each treatment cycle costing between 200,000 to 500,000 NTD, posing an unbearable financial burden to the patients and their families. Kuo Jing-Huan, the founder of Pei Yuan Health, who focuses on the development of artificial intelligence applications in the medical field, has introduced an 'Embryo Quality and Pregnancy Physiological Value Assessment System.' Through machine learning techniques, this system extracts and learns from a vast database of embryo images to create an embryo image analysis system. This development includes an embryo conception rate identification and pregnancy risk assessment system to aid doctors, significantly increasing the chances of successful artificial insemination.
Taiwan's artificial insemination success rate reaches 36%, ranking second worldwide.
Kuo Jing-Huan, who also serves as the Executive Director of the Health IoT Alliance at Taipei Medical University, states that Taiwan boasts a strong medical team, with an artificial insemination success rate of 36.7%, ranking second in the world, barely behind the United States at 37.5%, and far surpassing Mainland China's 22.5%. He mentioned that the U.S. FDA has already approved the Eeva Test, a smart testing system that selects embryos using delay imaging microscopes to collect real data during the embryo culture process. This system calculates and predicts which embryos are most likely to develop successfully and selects the best-suited fertilized embryos.
▲Illustration of Smart Embryo Selection Test
Additionally, international companies have begun to use artificial intelligence to help integrate complex datasets from multiple incompatible systems, including drug treatment programs and clinical pregnancy outcome information, as well as predicting the characteristics of successful in vitro fertilization (IVF) outcomes, which has also garnered Series A investment support.
In contrast domestically, fewer manufacturers or hospitals and clinics are involved. Pei Yuan Health hopes to collaborate with the professional medical team from Taipei Medical University to jointly develop a proprietary Taiwanese reproductive medicine case management platform. This platform uses AI systems to assist doctors in selecting from various treatment options the ones with the highest conception rates and making real-time adjustments based on different patient responses to fertility treatments, aiming to enhance Taiwan's international reputation in the reproductive medical industry.
Integrating AI Embryo Testing Algorithm for Marketing Abroad
Pei Yuan Health, based on its artificial intelligence embryo testing algorithm, combined with a developed Laboratory Information System (LIS) and time-lapse embryo incubators, conducts service verification. Utilizing a microservices framework to integrate testing equipment into the reproductive medicine laboratory management system for market sales, while also applying for the Institutional Review Board (IRB). They invite other reproductive medicine centers to participate in the experimental plan, submitting these clinical verification results to apply for an FDA Class II medical device application.
Kuo Jing-Huan points out that Mainland China, with its one-child policy lifted and an artificial insemination probability of only about 20%, represents a significant market opportunity. In 2020, Pei Yuan Health plans to actively invest in fertility clinics, including developing pre-pregnancy plans, establishing an ovum bank, attracting 10,000 clients, and accumulating investments in 5 joint venture clinics in Taiwan. The plan includes applying for AI technology FDA approval. In 2021, strategic investments in China will be made, completing a comprehensive factory export program, establishing brand authorization franchises, collaborating with 10 joint venture clinics in Taiwan and 50 franchise clinics in China, with the goal of giving more hope to parents desiring to have children.
「Translated content is generated by ChatGPT and is for reference only. Translation date:2024-05-19」